WallStSmart

Alibaba Group Holding Ltd (BABA)vsBrilliA Inc (BRIA)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Alibaba Group Holding Ltd generates 1651450% more annual revenue ($1.02T vs $61.56M). BABA leads profitability with a 8.9% profit margin vs 2.8%. BRIA trades at a lower P/E of 20.5x. BABA earns a higher WallStSmart Score of 50/100 (C-).

BABA

Buy

50

out of 100

Grade: C-

Growth: 4.0Profit: 6.0Value: 8.0Quality: 5.8
Piotroski: 5/9Altman Z: 2.39

BRIA

Avoid

32

out of 100

Grade: F

Growth: 2.0Profit: 5.0Value: 7.0Quality: 7.3
Piotroski: 4/9Altman Z: 5.01
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BABAUndervalued (+72.8%)

Margin of Safety

+72.8%

Fair Value

$560.44

Current Price

$131.50

$428.94 discount

UndervaluedFair: $560.44Overvalued
BRIAUndervalued (+37.6%)

Margin of Safety

+37.6%

Fair Value

$3.40

Current Price

$1.74

$1.66 discount

UndervaluedFair: $3.40Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BABA3 strengths · Avg: 8.7/10
Market CapQuality
$321.85B10/10

Mega-cap, among the largest globally

PEG RatioValuation
0.808/10

Growing faster than its price suggests

Price/BookValuation
2.0x8/10

Reasonable price relative to book value

BRIA1 strengths · Avg: 10.0/10
Altman Z-ScoreHealth
5.0110/10

Safe zone — low bankruptcy risk

Areas to Watch

BABA3 concerns · Avg: 2.7/10
Revenue GrowthGrowth
1.7%4/10

1.7% revenue growth

EPS GrowthGrowth
-70.9%2/10

Earnings declined 70.9%

Free Cash FlowQuality
$-32.37B2/10

Negative free cash flow — burning cash

BRIA4 concerns · Avg: 2.8/10
Market CapQuality
$41.00M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
2.8%3/10

2.8% margin — thin

Operating MarginProfitability
1.2%3/10

Operating margin of 1.2%

Revenue GrowthGrowth
-10.3%2/10

Revenue declined 10.3%

Comparative Analysis Report

WallStSmart Research

Bull Case : BABA

The strongest argument for BABA centers on Market Cap, PEG Ratio, Price/Book. PEG of 0.80 suggests the stock is reasonably priced for its growth.

Bull Case : BRIA

The strongest argument for BRIA centers on Altman Z-Score.

Bear Case : BABA

The primary concerns for BABA are Revenue Growth, EPS Growth, Free Cash Flow.

Bear Case : BRIA

The primary concerns for BRIA are Market Cap, Profit Margin, Operating Margin. Thin 2.8% margins leave little buffer for downturns.

Key Dynamics to Monitor

BABA is growing revenue faster at 1.7% — sustainability is the question.

BRIA generates stronger free cash flow (-5M), providing more financial flexibility.

Monitor INTERNET RETAIL industry trends, competitive dynamics, and regulatory changes.

Bottom Line

BABA scores higher overall (50/100 vs 32/100). BRIA offers better value entry with a 37.6% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Alibaba Group Holding Ltd

CONSUMER CYCLICAL · INTERNET RETAIL · USA

Alibaba Group Holding Limited, also known as Alibaba Group and Alibaba.com, is a Chinese multinational technology company specializing in e-commerce, retail, Internet, and technology. Founded on 28 June 1999 in Hangzhou, Zhejiang, the company provides consumer-to-consumer (C2C), business-to-consumer (B2C), and business-to-business (B2B) sales services via web portals, as well as electronic payment services, shopping search engines and cloud computing services. It owns and operates a diverse portfolio of companies around the world in numerous business sectors.

BrilliA Inc

CONSUMER CYCLICAL · APPAREL RETAIL · USA

BrilliA Inc. is a pioneering biotechnology firm focused on advancing skin health and regenerative medicine by developing innovative solutions for wound healing and enhancing patient quality of life. Leveraging cutting-edge proprietary technologies, BrilliA aims to address critical unmet medical needs in the healthcare sector. Committed to rigorous research and development, the company is strategically positioned to transform scientific breakthroughs into impactful therapeutic products, reinforcing its leadership in a dynamic and rapidly evolving market.

Visit Website →

Want to dig deeper into these stocks?